Research Article

Protective Effects of PPARγ on Renal Ischemia-Reperfusion Injury by Regulating miR-21

Ruizhen Huang, Cong Zou, Chiyu Zhang, Xing Wang, Xin Zou, Zhengjie Xiang, Zewei Wang, Bin Gui, Tao Lin, and Honglin Hu

1Department of Urology, The Second Affiliated Hospital of Nanchang University, Nanchang, China
2Department of Endocrinology, The Fourth Affiliated Hospital of Nanchang University, Nanchang, China

Correspondence should be addressed to Honglin Hu; honglinhu@126.com

Received 17 June 2022; Accepted 17 August 2022; Published 30 August 2022

1. Introduction

Renal ischemia-reperfusion injury (RIRI) is a common pathological process that causes kidney injury and severe complications such as acute renal failure. Complicated molecular mechanisms, including the accumulation of reactive oxygen species (ROS), apoptosis, and inflammatory cell infiltration, are reported to be pivotal in the process of RIRI [1, 2]. However, elaborating the exact mechanisms of RIRI is difficult, which makes RIRI a challenge during clinical therapy.

Activation of peroxisome proliferator-activated receptor γ (PPARγ) is important in protecting organs from IRI [3]. As kidneys have an abundant blood supply, they are sensitive to ischemia, and even transient ischemia caused by various reasons may induce severe renal reperfusion injury. RIRI is associated with high morbidity and mortality. We previously demonstrated that the PPARγ synthetic ligand pioglitazone exerts its renoprotective functions by inhibiting apoptosis, alleviating oxidative stress, and enhancing autophagy in in vitro and in vivo models [4–6]. Moreover, it seems that RIRI-induced inflammatory and oxidative responses are potentially ameliorated by administering pioglitazone, with inhibition of the NF-κB signaling pathway, and alleviated renal insults in rats [7]. The crucial roles of modulating NF-κB signaling pathway-mediated inflammation and oxidative stress in IRI have also been demonstrated by other researchers [8, 9], which may provide a theoretical basis for the exploration of novel targets and pathways in RIRI therapy. In this study, we further investigated the underlying molecular mechanisms of the nuclear transcription factor PPARγ in RIRI.
As an important member of the microRNA family, microRNA-21 (miR-21) has been studied as a tumor-related gene in previous studies. Recent studies on miRNA-21 have shown that it is also closely associated with the pathological process of IRI. Since Godwin et al. identified the miRNA signature of RIRI [10], substantial efforts have been made to understand the relationship between miRNAs and organ IRI amelioration. The protective effects of miR-21 in RIRI have been demonstrated in our previous studies, and the levels of blood urea nitrogen (BUN) and creatinine in the miR-21 overexpression group were lower than those in the corresponding control group [11]. We explored the effects of miR-21 and PPARγ as well as the crosstalk between miR-21 and PPARγ.

2. Materials and Methods

2.1. Cell Culture. The NRK-52E cell line was provided by Procell Life Science & Technology Co., Ltd. The cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) containing 1% penicillin-streptomycin and 10% fetal bovine serum (FBS; Gibco, Grand Island, NY, USA) in T-25 culture flasks at 37°C under 5% CO2.

2.2. Cell Transfection. PPARγ overexpression (OE) plasmid or shRNA (Hanbio, Shanghai, China) was transfected to regulate PPARγ expression. miR-21 mimic and inhibitor (Hanbio, Shanghai, China) were transfected to regulate miR-21 expression. For cell transfection, Lipo3000 transfection reagent (Invitrogen, Carlsbad, CA, USA) was used, according to the manufacturer’s instructions.

2.3. H/R Protocol. The cells were cultured to the logarithmic phase, and the H/R protocol was performed as follows. The hypoxic condition was realized in a constant temperature three-gas cell incubator, and the incubator was subjected to 95% N2 and 5% CO2 for 4 h. For reoxygenation, the culture was placed in a three-gas cell incubator, and the incubator was subjected to hypoxic condition was realized in a constant temperature 2.5°C under 5% CO2. For reoxygenation, the culture was placed in a three-gas cell incubator, and the incubator was subjected to 95% N2 and 5% CO2 for 4 h. For reoxygenation, the culture was placed in a three-gas cell incubator, and the incubator was subjected to hypoxic condition was realized in a constant temperature 37°C under 5% CO2 conditions for 12 h.

2.4. Cell Counting Kit-8 (CCK-8) Assay. To investigate cell viability, a CCK-8 (US Everbright Inc., China) assay was performed. Cells were seeded at a density of 8000 cells/well into 96-well plates before the assay was performed. The reagent (10 μL) was added after incubation at 37°C for 2 h, and a microplate reader was added; the absorbance was measured at a wavelength of 450 nm (A450).

2.5. Determination of Tumor Necrosis Factor-α (TNF-α) and Lactate Dehydrogenase (LDH) Levels. The cell culture medium was collected for each group. LDH commercial kit (Solarbio, Beijing, China) was used to examine the protein concentration and was kept consistent. Proteins were separated by electrophoresis on a 10% sodium dodecyl sulfate-(SDS-) polyacrylamide gel. The proteins were transferred to polyvinylidene fluoride (PVDF) membranes, and 5% skimmed milk was used to seal the PVDF membrane at room temperature for 1 h. Then, the anti-PPARγ (Proteintech, Wuhan, China, 1:2000), anti-caspase-3 (Proteintech, Wuhan, China, 1:1000), anti-caspase-3 (Proteintech, Wuhan, China, 1:200), and anti-GAPDH (Proteintech, Wuhan, China, 1:5000) primary antibodies were incubated overnight at a temperature of 4°C. The next day, after incubation with HRP-conjugated secondary antibodies, an ECL (US Everbright, China) solution was used for further analysis.

2.6. Flow Cytometric Analysis. Cells were washed twice with PBS, harvested with trypsin solution without EDTA, collected, and centrifuged at 1,000 rpm for 5 min. The apoptosis rate was detected for the resulting cells. All procedures were based on FITC-Annexin V and PI Apoptosis Kit (US Everbright Inc, China). After mixing with 300 μL of prechilled 1x binding buffer for each tube, further detection was realized using a flow cytometer.

2.7. Dual-Luciferase Reporter Assay. To confirm the relationship between miR-21 and the target genes, the synthesized wild-type (wt) and mutant (mu) luciferase reporter plasmids (Hanbio, Shanghai, China) were used for luciferase reporter assays. The prepared NRK-52E cells were seeded in a six-well plate, and after the cells reached 80% confluence, cotransfections of wt-PDCD4 or mu-PDCD4 plasmids and miR-21 mimics or miR-21 negative controls were performed using Lipofectamine 3000 (Thermo Fisher, USA). Six hours later, the culture medium was replaced, and 48 h after transfection, the cells were collected for detection. Dual-luciferase activity was detected using a commercial Dual-Luciferase Reporter Assay Kit (TransGen Biotech, Beijing, China) according to the manufacturer’s instructions.

2.8. Western Blotting. Total protein of NRK-52E cells for each group was extracted using a RIPA lysis solution, and a bicinchoninic acid (BCA) protein determination assay (Solarbio, Beijing, China) was used to examine the protein concentrations and was kept consistent. Proteins were separated by electrophoresis on a 10% sodium dodecyl sulfate-(SDS-) polyacrylamide gel. The proteins were transferred to polyvinylidene fluoride (PVDF) membranes, and 5% skimmed milk was used to seal the PVDF membrane at room temperature for 1 h. Then, the anti-PPARγ (Proteintech, Wuhan, China, 1:2000), anti-caspase-3 (Proteintech, Wuhan, China, 1:1000), anti-caspase-3 (Proteintech, Wuhan, China, 1:200), and anti-GAPDH (Proteintech, Wuhan, China, 1:5000) primary antibodies were incubated overnight at a temperature of 4°C. The next day, after incubation with HRP-conjugated secondary antibodies, an ECL (US Everbright, China) solution was used for further analysis.

2.9. Real-Time PCR Assay. Total RNA was extracted using the TransZol Up reagent (TransGen Biotech, Beijing, China). The concentrations and purity of the samples were determined using an ultraviolet spectrophotometer. Reverse transcription was performed to synthesize cDNA using the EasyScript® One-Step gDNA Removal and cDNA Synthesis SuperMix reagent Kit (TransGen Biotech, Beijing, China) according to the manufacturer’s instructions, and the SYBR Premix Ex Taq kit (Takara, Dalian, China) was then used for RT-PCR. The following sequences were used: GAPDH (sense: 5′-GAAAGACACCAACCGGCACTCAG-3′, antisense: 5′-TCATGAATGCATCTCTTTCG-3′), U6 (sense: 5′-CTCCTATGCAGTCGACCA-3′, antisense: 5′-AAGGCT TCACAATTGCGCT-3′), PPARγ (sense: 5′-GGACGCT TGAAGAGAGAGACCTG-3′, antisense: 5′-CCTGGTCTTC GTCTGAGTATG-3′), PDCD4 (sense: 5′-TTGAGCAGC
2.10. Animal Procedures. Pathogen-free male C57BL/6 mice (8–10 weeks old, weighing 18–20 g) were obtained from the Laboratory Animal Center of Nanchang University (Nanchang, Jiangxi, China). This study was assessed and approved by the Ethics Committee for Animal Experiments of the Second Affiliated Hospital of Nanchang University.

For renal transfection, the designed overexpression PPARγ recombinant adeno-associated virus (AAV9) (Hanbio, Shanghai, China) was injected directly into the kidneys. Preoperative fasting was performed for 8–12 h before surgery, and the rats were anesthetized intraperitoneally by administering pentobarbital sodium (50 mg/kg). When fully anesthetized, the left kidney was exposed via a 1.5 cm incision along the median abdominal line, and vehicles were injected into three to four sites with recombinant AAV [12]. Four weeks after the injection, antagoniR-21 and premiR-21 (RiboBio, Guangzhou, China) were used for miR-21 regulation. AntagonimR-21 and premiR-21 were injected via tail veins into the mice for 3 consecutive days. The mice were sacrificed for kidney isolation, quickly frozen in liquid nitrogen, and stored at −80°C for further analysis. The PPARγ-AAV9 transfection efficiency and miR-21 expression levels were measured.

2.11. Mouse Model of RIRI. Mice were abstained for 8–12 h before the construction of the RIRI model. The mice were anesthetized by intraperitoneal administration of pentobarbital sodium (50 mg/kg). Following a 1.5–2 cm incision along the median abdominal line, the renal pedicles were bluntly dissected, and RIRI was induced by bilateral clamping of the renal arteries. Once the color of the kidneys turned into a paler shade, occlusion was verified. After the kidneys were subjected to pedicle occlusion for 45 min, the microvascular clamps were removed from the pedicles, and the reperfusion stage was immediately implemented. Mice were sacrificed for further analysis 24 h after reperfusion.

2.12. Assessment of Renal Function. Blood samples were collected from the orbital vein of the mice into centrifuge tubes 24 h after reperfusion. Serum was obtained by centrifuging the blood samples at 3,000 rpm for 10 min. Serum creatinine (Scr) and blood urea nitrogen (BUN) levels were examined according to the manufacturer’s instructions to assess renal function, and commercial detection kits were obtained from the Nanjing Jiancheng Bioengineering Institute (Nanjing, China).

2.13. Histopathologic Evaluation of Kidney. The kidneys of euthanized mice in different groups were collected 24 h after reperfusion. For histopathological examination, the kidneys were dissected coronally and fixed using a paraformaldehyde tissue fixator, embedded in paraffin, and sliced into 4 mm sections for hematoxylin and eosin (H&E) staining. Morphological changes in renal tissue were observed using an optical microscope. The degree of renal tubular necrosis was assessed according to the method described by Zou et al. [7]. A maximum score of 4 indicates the highest degree of necrosis, 0 = normal kidney; 1 = minimal necrosis, <5% necrotic renal tubular involvement; 2 = mild necrosis, 5%–25% involvement; 3 = moderate necrosis, 25%–75% involvement; and 4 = severe, >75% involvement.

2.14. Immunohistochemical (IHC) Analysis. An IHC assay was used to examine PPARγ and PDCD4 expression in the kidneys. The sacrificed kidney tissues were embedded in paraffin and cut into 4 μm thick sections. The samples were deparaffinized with xylene and rehydrated with pure ethanol. BSA (3%) was added to the circle to evenly cover the tissue sections, which were then sealed for 60 min at room temperature. The sealing solution was gently removed, and the PPARγ (Cell Signalling Technology; USA) and PDCD4 (Cell Signalling Technology; USA) primary antibodies were used at a dilution of 1:200 for incubation overnight at 4°C. The sections were placed in PBS and washed by shaking on a decolorizing shaker thrice for 5 min each. After the sections were shaken slightly and dried, the tissues were covered with HRP-labeled secondary antibodies. After incubation with DAB and counterstaining with hematoxylin, the images were collected using light microscopy.

2.15. Immunofluorescence Analysis. Kidney tissues were embedded in paraffin and cut into 4 μm slides. The samples were deparaffinized with xylene and rehydrated with pure ethanol. Blocking was performed with 5% bovine serum albumin for 2 h at room temperature. The sealing solution was gently removed; slides were incubated with the PPARγ primary antibodies (1:200; Cell Signalling Technology; USA) and PDCD4 (1:600; Cell Signalling Technology; USA) primary antibody overnight at 4°C. The slides were washed three times with PBS, and then, the objective tissue was covered with a secondary antibody and incubated at room temperature for 60 min in the dark. After incubation with the DAPI solution at room temperature for 20 min in the dark, images were acquired using a fluorescence microscope.

2.16. TUNEL Assay. The terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling assay (TUNEL) was used for examining cell apoptosis. The sacrificed kidney tissues were embedded in paraffin and cut into 4 μm thick sections. The samples were deparaffinized with xylene and rehydrated with pure ethanol. A 0.5% Triton-X-100 working solution was used for permeabilization, incubated at room temperature for 20 min, and washed thrice with PBS. The TUNEL reaction was performed according to the instructions of the TUNEL Detection Kit (Servicebio, Wuhan, China). After incubation with the DAPI solution at room temperature for 10 min, images were collected using a fluorescence microscope.

2.17. Statistical Analysis. All data were statistically analyzed using the GraphPad Prism software (version 8.0). Quantitative data were expressed as mean (x) ± S.E. Differences between two groups were compared using the t-test, and
Oxidative Medicine and Cellular Longevity

Figure 1: Continued.
multiple groups were compared using one-way ANOVA along with Tukey’s post hoc multiple-comparisons test. \( p < 0.05 \) was considered statistically significant.

3. Results

3.1. PPAR\( \gamma \) and miR-21 Improved Cell Viability after the H/R Procedure. A CCK8 assay was performed to evaluate the viability of each group. As shown in Figure 1, cells subjected to H/R showed significantly decreased cell viability compared with the negative control (NC) group. However, cell viability in cells subjected to H/R was significantly improved when PPAR\( \gamma \) and miR-21 were upregulated as compared to that in the H/R alone group. Interestingly, when both PPAR\( \gamma \) and miR-21 were upregulated simultaneously in the NRK-52E cells, cell viability was significantly improved compared to that in the H/R group. miR-21 may have little effect on cytoprotection under conditions of low PPAR\( \gamma \) expression.

3.2. Regulation of PPAR\( \gamma \) and miR-21 Influences LDH and TNF-\( \alpha \) Levels after H/R. The LDH and TNF-\( \alpha \) levels were measured to evaluate the cytoprotective effects of PPAR\( \gamma \) and miR-21 against H/R injury. In cells subjected to H/R injury, LDH and TNF-\( \alpha \) are released from intracellular organelles. Therefore, LDH and TNF-\( \alpha \) levels were examined to assess the degree of H/R injury. Levels of LDH and TNF-\( \alpha \) increased dramatically in the H/R group, and PPAR\( \gamma \) and miR-21 had a cytoprotective effect. Overexpression of PPAR\( \gamma \) significantly decreased cell injury, whereas interfering with PPAR\( \gamma \) expression led to more severe cell injury than in the H/R group (Figures 2(a) and 2(d)). miR-21 showed a similar cytoprotective effect (Figures 2(b) and 2(e)). Furthermore, cotransfection with PPAR\( \gamma \) and miR-21 resulted in lower LDH and TNF-\( \alpha \) levels when subjected to H/R injury. However, the protective effect was weakened in the cotransfection groups when either PPAR\( \gamma \) or miR-21 was downregulated (Figures 2(c) and 2(f)).

3.3. PPAR\( \gamma \) and miR-21 Could Mitigate Cell Apoptosis after the H/R Procedure. To further determine the cytoprotective effects of PPAR\( \gamma \) and miR-21, flow cytometric analysis was performed to examine the NRK-52E cell apoptosis levels in each group (Figure 3). Our study indicated that the overexpression of PPAR\( \gamma \) and miR-21 reduced the proportion of apoptotic cells during H/R. When PPAR\( \gamma \) and miR-21 were upregulated simultaneously, apoptosis in NRK-52E cells during H/R was ameliorated more than merely upregulating PPAR\( \gamma \) or miR-21. However, silencing of PPAR\( \gamma \) partially reversed this protection, even upregulating miR-21 expression, and cell apoptosis was worse than that in the mimic.
These results suggest that PPARγ and miR-21 could attenuate cell apoptosis, indicating the pivotal role of PPARγ in cytoprotection.

3.4. PPARγ Could Upregulate the miR-21 Levels. As the transcription factor PPARγ is involved in different stages of miRNA biogenesis, its protective effects during H/R injury may be due to the underlying cross-talk between PPARγ and miR-21. To identify the mechanism of PPARγ and miR-21 regulation during H/R, we examined gene expression using qPCR (Figure 4(a)). In the H/R group, both PPARγ and miR-21 expression decreased, and the application of miR-21 mimic and inhibitor effectively regulated miR-21 expression, indicating that transfection was efficient. Furthermore, the miR-21 level in the PPARγ overexpression group was higher than that in the NC group, and the miR-21 level was decreased by silencing PPARγ expression, whereas it seems that activation of miR-21 was unable to affect PPARγ mRNA expression. However, no significant difference was observed between the miR-21 mimic and inhibitor groups. These results demonstrate that the transcription factor PPARγ could upregulate miR-21 levels. In addition, the cytoprotection of PPARγ may be partially mediated by the upregulation of miR-21 levels.
To examine the molecular mechanism of PPARγ-mediated protection of cells against H/R injury, a dual-luciferase reporter assay was performed. It was observed that the miR-21 downregulated promoter activity of PDCD4 by directly targeting 3′-UTR. In other words, the cytoprotection effect of PPARγ on cell H/R injury may partially regulate the miR-21 expression and thus downregulated its target PDCD4 (Figure 4(b)).

3.5. PPARγ Alleviates H/R Injury by Downregulating Caspase-3 and PDCD4 Levels. In the caspase-dependent apoptosis pathway, caspase-3 is the key molecule that stimulates cell apoptosis. PDCD4 is also regarded as a pre-apoptotic gene. To ascertain the role of PPARγ and miR-21 in H/R injury, we examined the expressions of PPARγ, caspase-3, and PDCD4 using western blotting. We found that H/R induced downregulation of PPARγ proteins, and no significant difference was noted between the miR-21 mimic and inhibitor groups (data not shown). The expression of cleaved caspase-3 and PDCD4 was significantly higher in cells subjected to H/R injury than in the NC group. The overexpression of PPARγ partially reversed their expression, and cleaved caspase-3 and PDCD4 were increased when PPARγ expression was...
knocked down (Supplementary Figure 1). Additionally, miR-21 expression is related to the expression of cleaved caspase-3 and PDCD4. Upregulated miR-21 expression in the mimic group was accompanied by a decrease in PDCD4 expression, which was blocked by the miR-21 inhibitor (Supplementary Figure 2). In the mimic+HR group, the expression of cleaved caspase-3 and PDCD4 was significantly reduced compared with that in the HR group. When we cotransfected the overexpression PPARγ plasmid and miR-21 mimic, H/R-induced cleaved caspase-3 and PDCD4 expression was significantly ameliorated compared to the OE-PPARγ+HR or miR-21 mimic+HR groups (Figure 5).

3.6. PPARγ and miR-21 Improved Kidney Damage in Mice Subjected to I/R Injury. A RIRI model was established to investigate the effects of PPARγ and miR-21 on renal tissues. H&E staining was used to evaluate renoprotective effects (Figures 6(a) and 6(b)). IRI resulted in severe histopathological damage in the renal tissue, and serious tubular dilatation, congestion, edema, vacuolization, and tubular necrosis were noted in the IRI group. However, pretreatment

![Figure 4](image-url)
Figure 5: Continued.
Figure 5: Expression of PPARγ, PDCD4, and cleaved caspase-3 proteins: (a) PPARγ and cleaved caspase-3 protein expressions in PPARγ overregulated and simultaneously miR-21 cotransfection groups; (b) PDCD4 protein expressions in PPARγ overregulated and simultaneously miR-21 cotransfection groups; (c) PPARγ and cleaved caspase-3 protein expressions in PPARγ downregulated and simultaneously miR-21 cotransfection groups; (d) PDCD4 protein expressions in PPARγ downregulated and simultaneously miR-21 cotransfection groups (A represents comparison with NC group, \( p < 0.05 \); B represents comparison with HR group, \( p < 0.05 \); C represents comparison with mimic+HR group, \( p < 0.05 \); D represents comparison with OE-PPARγ+HR group, \( p < 0.05 \); E represents comparison with inhibitor+HR group, \( p < 0.05 \)).
Figure 6: Continued.
with premiR-21 significantly ameliorated this damage. The amelioration of tissue damage was also observed in the PPARγ transfection group, indicating the renoprotective effects of PPARγ.

Scr and BUN levels were used to assess renal function. Collectively, PPARγ and miR-21 could effectively protect the kidney against IRI, and Scr and BUN levels were significantly alleviated in the AAV9-PPARγ+IRI and premiR-21+IRI groups. It is worth noting that despite both PPARγ and miR-21 having renoprotective functions, the AAV9-PPARγ+IRI group had lower Scr and BUN levels than the premiR-21+IRI group, suggesting that PPARγ-mediated miR-21 upregulation was involved in renoprotective effects (Figures 6(c) and 6(d)).

3.7. PPARγ and miR-21 Decreased Apoptotic Cell Death in the Kidney Tissue. Groups that underwent IRI had significantly higher apoptosis rates than those in the non-IRI groups. No significant difference in apoptotic cells was observed between the PBS+sham and other sham groups. In comparison with the IRI group, the apoptosis rates in the AAV9-PPARγ+IRI and premiR-21+IRI groups were significantly lower, while the number of apoptotic cells in the antagonomiR-21+IRI group was significantly higher. In addition, significant differences were noted in the AAV9-PPARγ+premiR-21+IRI, AAV9-PPARγ+antagomiR-21+IRI, and AAV9-PPARγ+IRI groups. Pretreatment with premiR-21 significantly protected the renal tissues against IRI, and the application of antagoniR-21 resulted in poor renal cell apoptosis. Interestingly, the AAV9-PPARγ+IRI and premiR-21+IRI groups showed that PPARγ activation had a better protective effect than activation of miR-21. These results suggest that PPARγ and miR-21 could decrease apoptotic cell death in kidney tissue and that they play two different roles in renal protection (Figure 7).

3.8. Immunohistochemistry and Immunocytochemical Analysis in Kidney. PPARγ and PDCD4 expressions were considered the main marker of this study. Comparison of immunohistochemical staining showed that PPARγ expression in the kidney was significantly increased after the PPARγ overexpressed AAV9 was injected directly into the kidney compared to the sham group mice. IRI induced PPARγ expression, whereas miR-21 did not affect PPARγ expression in mouse kidney tissues (Figure 8(a)).

Similar to the western blotting results, PDCD4 expression was significantly increased in mice subjected to RIRI, and PPARγ and miR-21 overexpression was associated with reduced PDCD4 protein levels in mice subjected to RIRI. In contrast, dual overexpression of PPARγ and miR-21 in mice resulted in lower PDCD4 expression than that of the AAV9-PPARγ+IRI and premiR-21+IRI groups, and the PDCD4 was partially reversed by miR-21 blockade (Figure 8(b)).

To investigate the localization of PPARγ and PDCD4 expression, immunofluorescence analysis was performed on the kidney tissues. As shown in the figure, the perinuclear location in kidney tissues was observed during PPARγ expression. Moreover, its expression decreased after being subjected to IRI and was elevated by transfection with AAV9-PPARγ. PDCD4 was expressed in the cellular matrix of kidney tissues. These results suggest that after the ischemic insult in the kidney tissues, PPARγ expression was...
Figure 7: TUNEL assay to evaluate the apoptosis of kidney tissues (n = 5): (a) representative photograph of TUNEL assay (scale bar 20 μm); (b) quantitative analysis of TUNEL assay in the kidneys (A represents values compared to the sham group, p < 0.05; B represents values compared to the IRI group, p < 0.05; C represents values compared to the AAV9-PPARγ+IRI group, p < 0.05; D represents values compared to the premiR-21+IRI group, p < 0.05; E represents values compared to the antagomiR-21+IRI group, p < 0.05).
PBS+sham  AAV9-PPARγ+sham  PremiR-21+sham  Antagomir-21+sham

IRI  AAV9-PPARγ+IRI  PremiR-21+IRI  Antagomir-21+IRI

AAV9-PPARγ+premiR-21+IRI  AAV9-PPARγ+antagomir-21+IRI

PBS+sham  AAV9-PPARγ+sham  PremiR-21+sham  Antagomir-21+sham

IRI  AAV9-PPARγ+IRI  PremiR-21+IRI  Antagomir-21+IRI

AAV9-PPARγ+premiR-21+IRI  AAV9-PPARγ+antagomir-21+IRI

Figure 8: Continued.
downregulated and PDCD4 was elevated. Furthermore, no significant difference was noted in PPARγ by premiR-21 and antagomiR-21 pretreatment, whereas at least a portion of PDCD4 was induced by antagomiR-21 and IRI (Figures 8(c) and 8(d)).

4. Discussion

The major findings of our study are that in an in vitro H/R model, upregulation of PPARγ expression through the plasmid results in the amelioration of H/R injury. Knockdown of PPARγ in NRK-52E cells led to severe H/R injury. Besides, overexpression of miR-21 through miR-21 mimic protects NRK-52E cells against H/R injury, and the protective effect was reversed when miR-21 expression was knocked down by miR-21 inhibitor. Intriguingly, PPARγ appears to be superior to miR-21 in its protective effects. Further research suggests that the superior protective effects of PPARγ may be due to its contribution to the upregulation of the miR-21 levels. The mechanism by which PPARγ and miR-21 exert their effect is likely to be through apoptosis signaling and significant changes in caspase-3. PDCD4 protein expressions reveal that PPARγ ameliorates H/R injury partially via upregulating miR-21 expression and hence...
decreases miR-21 target PDCD4 expression where caspase-mediated apoptosis signaling is involved. Moreover, PPARγ and miR-21 protected mice against RIRI in an in vivo experimental model. These results suggest a potential renoprotective mechanism through which PPARγ mediates the miR-21/PDCD4/caspase-3 axis in RIRI.

PPARγ is a nuclear transcription factor that binds to the peroxisome proliferator responsive element (PPRE) as a heterodimer with retinoid X receptor (RXR). Once activated by its agonists, downstream transcription and expression effects are regulated [13]. The activation of PPARγ leads to the amelioration of renal, hepatic, cerebral, myocardial, and other tissues of IRI [14]. This indicates that PPARγ is a potential therapeutic mediator in IRI. Our previous studies mainly focused on the PPARγ agonist pioglitazone, which was used in type 2 diabetes, to protect against RIRI and the underlying molecular mechanisms. In this study, we directly regulated PPARγ expression via plasmids and found that PPARγ overexpression prevented apoptosis by upregulating miR-21, caspase-3, and PDCD4. The antiapoptosis of PPARγ was also reported by Wu et al. [15] who found that PPARγ overexpression by plasmid had a comparable antiapoptotic effect by upregulating Bcl-2 family proteins, but the antiapoptotic effects were abrogated by PPARγ downregulation when PPARγ siRNA was applied. Another study by Jiang et al. [16] investigated the anti-inflammatory effect of PPARγ on cerebral IRI. In their study, vagus nerve stimulation (VNS) treatment enhanced PPARγ expression, diminished the extent of the ischemic infarct, and alleviated neuronal injury in a rat cerebral IR model. Furthermore, the suppression of inflammatory cytokine secretion during the cerebral IRI process is a result of a PPARγ-mediated mechanism as PPARγ silencing exacerbates ischemic neuronal necrosis. As PPARγ accomplishes these antiapoptotic and anti-inflammatory effects without any exogenous ligands, we speculate that endogenous ligands may be involved in PPARγ activation and thus regulate the expression of non-coding RNA such as miR-21 during the IRI procedure.

miR-21 is upregulated in renal tubular epithelial cells subjected to H/R and in the kidneys following ischemic injury. Knockdown of miR-21 promoted cellular apoptosis and necrosis, whereas miR-21 overexpression downregulated cell death [10]. We previously found that in a RIRI model, IRI induced significant upregulation of miR-21 and exerted its antiapoptotic properties, which may be due to the suppression of PDCD4 and activation of caspase-3/8 fragments [11]. Our present study illustrated similar renoprotective functions of miR-21, and miR-21 was significantly downregulated in our in vitro H/R model. Combined with our previous research results, we suggest that miR-21 may be downregulated in the initial stage of IRI, and then, due to the self-defense response, it was upregulated, thereby performing protective functions in the serious disorder stage of cell injury. Researchers have found that in restenosis vascular smooth muscle cells, Bcl-2 is involved in miR-21-mediated cellular effects and miR-21 overexpression is associated with increased Bcl-2 expression [17]. However, research in breast cancer cells has revealed that miR-21 expression is inversely associated with Bcl-2 expression [18], which is fundamentally different from restenosis vascular smooth muscle cells. The controversial role of miR-21 in tissue injury may be correlated with the injury stage, histological differences, and mechanistic distinctiveness.

PDCD4 is a key factor in apoptosis. PDCD4 can activate caspase-3 and initiate apoptosis [19]. The antiapoptotic effect of miR-21 was partly mediated through its target genes PDCD4, and PDCD4 translational suppression by miR-21 has been demonstrated in the pathobiology of cancer cell proliferation [20, 21]. Overexpression of miR-21 reduced PDCD4 promoter activation by directly targeting the 3'-UTR region. Therefore, miR-21 expression was negatively correlated with PDCD4 [22]. These results support the concept that miR-21 functions as a mediator by a mechanism that involves translational repression of PDCD4. Our primary findings demonstrated that upregulation of PPARγ enhanced miR-21 expression, thus inhibiting PDCD4 expression, improving cell viability, and reducing apoptosis in IRI. PDCD4 may activate caspase-3 and promote cell apoptosis. In contrast, another study suggested that inactivation of miR-21 stimulated PDCD4 and induced pulmonary artery endothelial apoptosis through caspase-3 activation. This phenomenon was abrogated by miR-21 mimic transfection, and the PDCD4/caspase-3 axis was silenced, thus preventing apoptosis [23]. Collectively, our findings demonstrated that the underlying miR-21/PDCD4/caspase-3 axis on activation drives apoptosis both in vitro and in vivo. From another perspective, the underlying miR-21/PDCD4/caspase-3 pathway may participate in human IRI pathogenesis. Our findings underscore the potential utility of future clinical investigations targeting the miR-21/PDCD4/caspase-3 axis. In a study on pulmonary arterial hypertension, Green et al. [24] found that PPARγ activation can reduce the proliferation of vascular smooth muscle cells and affect disease progression by regulating miR-21 and affecting PDCD4 expression. In conclusion, combined with these results, intrinsic regulation may also exist between PPARγ and miR-21 during RIRI.

As a transcription factor, PPARγ is generally considered to be involved in the regulation of one or more classes of functionally related protein-coding genes, and PPARγ has been identified as a regulator of lipid metabolism and fibrosis [25]. Most miRNAs are transcribed from specific genes with specific promoters located throughout the genome. miRNAs have been confirmed to participate in the pivotal biological processes of posttranscriptional gene regulation [26]. Since transcription factors and miRNAs function as transcription and translation factors, little is known about their relationship. Fortunately, an increasing number of studies have begun to focus on elaborating the molecular mechanisms involved in pathophysiological procedures. In 2015, Dharap et al. used the PPARγ synthetic ligand rosiglitazone in adult rats before miRNA profiling was conducted using microarrays, and 28 miRNAs were found to be altered significantly after treatment with rosiglitazone [27]. A study conducted by Winkler et al. [28] demonstrated that PPARγ directly regulates a class of miRNAs that are functionally associated with antifibrotic properties. In their study, PPARγ was described as a key regulator in antifibrotic miRNA
regulation and miRNAs targeting key fibrosis-associated genes. Hence, the formation of an intricate coherent feed-forward loop among PPARγ, miRNAs, and the corresponding target gene plays a significant role in fibrosis regulation. In contrast, PPARγ and miRNAs may have diverse relationships other than the modulatory role of PPARγ in miRNAs. For example, PPARγ was identified as a miR-130b direct target in colorectal cancers [29], and miR-130b was also identified as an independent prognostic biomarker in glioma patients by targeting PPARγ [30]. In addition to miR-130b, miR-27a [31], miR-128 [32], and miR-19b [33] were proved to act as upstream mediators targeting PPARγ. miRNAs may have potential promoter regions in the PPREs. The miR-145 and miR-329 expression levels were significantly modulated by PPARγ expression vector transfection and were reversed by point mutations of PPREs in their promoters. Furthermore, transfection with miR-329 mimic and miR-145 mimic was demonstrated to activate PPARγ, suggesting underlying binding sites for miRNAs in the PPARγ promoter [27]. Mechanistically, miR-21 is regulated by the transcription factor PPARγ. Our study highlights the role of the master regulator of transcription factor PPARγ in miR-21 regulation. However, the regulatory function needs to be comprehensively considered in various pathologies, tissues, and biological procedures before the mechanism whereby PPARγ activation prevents RIRI can be elucidated.

5. Conclusion

In this study, we showed that both PPARγ and miR-21 had protective effects on RIRI to varying degrees, overexpression of PPARγ or miR-21 could mitigate the cell damage and cell apoptosis through regulating the apoptotic proteins, and there was an interaction between PPARγ and miR-21. Our findings underscore the potential utility of future clinical investigations, whereby PPARγ activation regulates the underlying miR-21/PDCD4 pathway, which may participate in human IRI pathogenesis.

Data Availability

The data that support the findings of this study are available from the corresponding author, upon reasonable request.

Conflicts of Interest

No conflicts of interest exist in the submission of this manuscript.

Authors’ Contributions

This study was designed by HH. RH, CZ, XW, ZX, TL, BG, and ZW conducted the study. RH, CZ, and XW analyzed and interpreted the data. RH drafted the manuscript and was responsible for revising it. Ruizhen Huang, Cong Zou, and Chiyu Zhang contributed equally to this work. The manuscript has been approved by all authors for publication.

Acknowledgments

Grants from the National Natural Science Foundation of China (No. 81860128) and Natural Science Foundation of Jiangxi Province Project (No. 20171BAB205016) supported this study.

Supplementary Materials

Supplementary Figure 1: expression of PPARγ, PDCD4, and cleaved caspase-3 proteins. (a) PPARγ and cleaved caspase-3 protein expression in PPARγ regulation groups. (b) PDCD4 protein expression in PPARγ regulation groups. (c) PDCD4 and cleaved caspase-3 protein expression in miR-21 regulation groups (a represents comparison with NC group, p < 0.05; b represents comparison with HR group, p < 0.05; c represents comparison with sh-PPARγ group, p < 0.05; d represents comparison with OE-PPARγ group, p < 0.05). Supplementary Figure 2: expression of PDCD4 and cleaved caspase-3 proteins (a represents comparison with NC group, p < 0.05; b represents comparison with HR group, p < 0.05; c represents comparison with mimic group, p < 0.05; d represents comparison with inhibitor group, p < 0.05). (Supplementary Materials)

References

[1] J. J. Friedewald and H. Rabb, “Inflammatory cells in ischemic acute renal failure,” Kidney International, vol. 66, no. 2, pp. 486–491, 2004.
[2] N. E. Kieran and H. Rabb, “Immune responses in kidney preservation and reperfusion injury,” Journal of Investigative Medicine, vol. 52, no. 5, pp. 310–314, 2004.
[3] S. Cuzzocrea, “Peroxisome proliferator-activated receptors gamma ligands and ischemia and reperfusion injury,” Vascular Pharmacology, vol. 41, no. 6, pp. 187–195, 2004.
[4] W. Chen, X. Xi, S. Zhang et al., “Pioglitazone protects against renal ischemia-reperfusion injury via the AMP-activated protein kinase-regulated autophagy pathway,” Frontiers in Pharmacology, vol. 9, p. 851, 2018.
[5] H. Hu, C. Zou, X. Xi, Z. Shi, G. Wang, and X. Huang. “Protective effects of pioglitazone on renal ischemia-reperfusion injury in mice,” The Journal of Surgical Research, vol. 178, no. 1, pp. 460–465, 2012.
[6] C. Zou, H. Hu, X. Xi, Z. Shi, G. Wang, and X. Huang, “Pioglitazone protects against renal ischemia-reperfusion injury by enhancing antioxidant capacity,” The Journal of Surgical Research, vol. 184, no. 2, pp. 1092–1095, 2013.
[7] G. Zou, Z. Zhou, X. Xi, R. Huang, and H. Hu, “Pioglitazone ameliorates renal ischemia-reperfusion injury via inhibition of NF-kB activation and inflammation in rats,” Frontiers in Physiology, vol. 12, article 707344, 2021.
[8] M. Cordaro, R. Fusco, R. D’Amico et al., “Cashew (Anacardium occidentale L.) nuts modulate the Nrf2 and NLRP3 pathways in pancreas and lung after induction of acute pancreatitis by cerulein,” Antioxidants, vol. 9, no. 10, p. 992, 2020.
[9] R. Fusco, M. Cordaro, R. Siracusa et al., “Consumption of Anacardium occidentale L. (cashew nuts) inhibits oxidative stress through modulation of the Nrf2/HO-1 and Nrf-kB pathways,” Molecules, vol. 25, no. 19, p. 4426, 2020.
[10] J. G. Godwin, X. Ge, K. Stephan, A. Jurisch, S. G. Tullius, and J. Iacomini, “Identification of a microRNA signature of renal
ischemia reperfusion injury,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 32, pp. 14339–14344, 2010.

[11] H. Hu, W. Jiang, X. Xi, C. Zou, and Z. Ye, “MicroRNA-21 attenuates renal ischemia reperfusion injury via targeting caspase signaling in mice,” American Journal of Nephrology, vol. 40, no. 3, pp. 215–223, 2014.

[12] M. S. Lipkowitz, B. Hanss, N. Tulchin et al., “Transduction of renal cells in vitro and in vivo by adeno-associated virus gene therapy vectors,” Journal of the American Society of Nephrology, vol. 10, no. 9, pp. 1908–1915, 1999.

[13] K. L. Gearing, M. Gottlicher, M. Teboul, E. Widmark, and J. A. Gustafsson, “Interaction of the peroxisome-proliferator-activated receptor and retinoid X receptor,” Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 4, pp. 1440–1444, 1993.

[14] R. Huang, C. Zhang, X. Wang, and H. Hu, “PPARγ in ischemia-reperfusion injury: overview of the biology and therapy,” Frontiers in Pharmacology, vol. 12, article 600618, 2021.

[15] J. S. Wu, T. N. Lin, and K. K. Wu, “Rosiglitazone and PPAR-γ overexpression protect mitochondrial membrane potential and prevent apoptosis by upregulating anti-apoptotic Bcl-2 family proteins,” Journal of Cellular Physiology, vol. 220, no. 1, pp. 58–71, 2009.

[16] Y. Jiang, L. Li, B. Liu, Y. Zhang, Q. Chen, and C. Li, “PPARγ upregulation induced by vagus nerve stimulation exerts anti-inflammatory effect in cerebral ischemia/reperfusion rats,” Medical Science Monitor, vol. 21, pp. 268–275, 2015.

[17] R. Ji, Y. Cheng, J. Yue et al., “MicroRNA expression signature and antisense-mediated depletion reveal an essential role of microRNA in vascular neointimal lesion formation,” Circulation Research, vol. 100, no. 11, pp. 1579–1588, 2007.

[18] N. S. Wickramasinghe, T. T. Manavalan, S. M. Dougherty, K. A. Biggs, Y. Li, and C. M. Klinge, “Estradiol downregulates miR-21 expression and increases miR-21 target gene expression in MCF-7 breast cancer cells,” Nucleic Acids Research, vol. 37, no. 8, pp. 2584–2595, 2009.

[19] N. Bitomsky, N. Wethkamp, R. Marikkannu, and K. H. Klemmnaun, “siRNA-mediated knockdown of Pdcd4 expression causes upregulation of p21(Waf1/Cip1) expression,” Oncogene, vol. 27, no. 35, pp. 4820–4829, 2008.

[20] X. Li, K. Huang, and J. Yu, “Inhibition of microRNA-21 upregulates the expression of programmed cell death 4 and phosphatase tensin homologue in the A431 squamous cell carcinoma cell line,” Oncology Letters, vol. 8, no. 1, pp. 203–207, 2014.

[21] Y. B. Guo, T. F. Ji, H. W. Zhou, and J. L. Yu, “Effects of microRNA-21 on nerve cell regeneration and neural function recovery in diabetes mellitus combined with cerebral infarction rats by targeting PDCD4,” Molecular Neurobiology, vol. 55, no. 3, pp. 2494–2505, 2018.

[22] Z. Lu, M. Liu, V. Stribinskiis et al., “MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene,” Oncogene, vol. 27, no. 31, pp. 4373–4379, 2008.

[23] K. White, Y. Dempse, P. Caruso et al., “Endothelial apoptosis in pulmonary hypertension is controlled by a microRNA/programmed cell death 4/caspase-3 axis,” Hypertension, vol. 64, no. 1, pp. 185–194, 2014.

[24] D. E. Green, T. C. Murphy, B. Y. Kang et al., “Peroxisome proliferator-activated receptor-γ enhances human pulmonary artery smooth muscle cell apoptosis through microRNA-21 and programmed cell death 4,” American Journal of Physiology. Lung Cellular and Molecular Physiology, vol. 313, no. 2, pp. L371–L383, 2017.

[25] L. Michalik, B. Desvergne, and W. Wahli, “Peroxisome-proliferator-activated receptors and cancers: complex stories,” Nature Reviews. Cancer, vol. 4, no. 1, pp. 61–70, 2004.

[26] N. Bushati and S. M. Cohen, “MicroRNA functions,” Annual Review of Cell and Developmental Biology, vol. 23, no. 1, pp. 175–205, 2007.

[27] A. Dharap, C. Pokrzywa, S. Murali, B. Kaimal, and R. Vemuganti, “Mutual induction of transcription factor PPARγ and microRNAs miR-145 and miR-329,” Journal of Neurochemistry, vol. 135, no. 1, pp. 139–146, 2015.

[28] I. Winkler, C. Bitter, S. Winkler et al., “Identification of Ppar-modulated miRNA hubs that target the fibrotic tumor microenvironment,” Proceedings of the National Academy of Sciences of the United States of America, vol. 117, no. 1, pp. 454–463, 2020.

[29] T. Colangelo, A. Fucci, C. Votino et al., “MicroRNA-130b promotes tumor development and is associated with poor prognosis in colorectal cancer,” Neoplasia, vol. 15, no. 9, pp. 1086–1099, 2013.

[30] X. Sheng, H. Chen, H. Wang et al., “MicroRNA-130b promotes cell migration and invasion by targeting peroxisome proliferator-activated receptor gamma in human glioma,” Bio-medicine & Pharmacotherapy, vol. 76, pp. 121–126, 2015.

[31] L. Wu, Q. Wang, F. Guo et al., “MicroRNA-27a induces mesangial cell injury by targeting of PPARγ and its in vivo knockdown prevents progression of diabetic nephropathy,” Scientific Reports, vol. 6, no. 1, article 26072, 2016.

[32] Y. Liu, Y. Zhang, P. Liu et al., “MicroRNA-128 knockout inhibits the development of Alzheimer’s disease by targeting PPARγ in mouse models,” European Journal of Pharmacology, vol. 843, pp. 134–144, 2019.

[33] J. Wang, X. Xu, P. Li, B. Zhang, and J. Zhang, “HDAC3 protects against atherosclerosis through inhibition of inflammation via the microRNA-19b/PARP γ/NF-κB axis,” Atherosclerosis, vol. 323, pp. 1–12, 2021.